Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
出 版 商：Global Markets Direct
出版日期：2014/02/28
頁 數：199頁
文件格式：PDF
價 格：
USD 2,000 (Single-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
USD 4,000 (Multi-User License)
USD 6,000 (Global-User License)
Metastatic Pancreatic Cancer - Pipeline Review, H1 2014
Summary
Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Pancreatic Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Summary
Global Markets Direct’s, ‘Metastatic Pancreatic Cancer - Pipeline Review, H1 2014’, provides an overview of the Metastatic Pancreatic Cancer’s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Metastatic Pancreatic Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Pancreatic Cancer and special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Metastatic Pancreatic Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Metastatic Pancreatic Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Metastatic Pancreatic Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Metastatic Pancreatic Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Metastatic Pancreatic Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Metastatic Pancreatic Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Pancreatic Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Pancreatic Cancer - Overview 11
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 16
Metastatic Pancreatic Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Metastatic Pancreatic Cancer - Products under Development by Companies 20
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 22
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Adherex Technologies Inc. 24
AstraZeneca PLC 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
FibroGen, Inc. 28
Novartis AG 29
Pfizer Inc. 30
Celgene Corporation 31
Bayer AG 32
Halozyme Therapeutics, Inc. 33
Momenta Pharmaceuticals, Inc. 34
Immunomedics, Inc. 35
Synta Pharmaceuticals Corp. 36
NanoCarrier Co., Ltd. 37
Rexahn Pharmaceuticals, Inc. 38
Insys Therapeutics, Inc. 39
OncoMed Pharmaceuticals, Inc. 40
Merrimack Pharmaceuticals, Inc. 41
Pharma Mar, S.A. 42
AB Science 43
Oncovir, Inc. 44
ParinGenix, Inc. 45
Regulon Inc. 46
Fountain Biopharma Inc. 47
Oncozyme Pharma Inc. 48
AbbVie Inc. 49
Metastatic Pancreatic Cancer - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
paclitaxel albumin-bound - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
irinotecan sucrosofate liposomal - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
masitinib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
cisplatin liposomal - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
cisplatin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
refametinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
selumetinib sulfate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
trametinib dimethyl sulfoxide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
docetaxel - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
paclitaxel albumin-bound - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ganetespib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RX-0201 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
irinotecan sucrosofate liposomal - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PGX-100 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
lurbinectedin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
yttrium Y 90 clivatuzumab tetraxetan - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Cancer Inhibitor Macrobeads - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
TL-118 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
LY-2090314 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
hydroxychloroquine - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
LY-2495655 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
PEGPH-20 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
M-402 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
pentamidine isethionate - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
veliparib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
galunisertib - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
ADH-1 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
FG-3019 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
demcizumab - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
LCL-161 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
bevacizumab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
PD-0325901 + PF-05212384 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Poly-ICLC - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
rottlerin - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
FB-704A - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
LY-2109761 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Ceramide Analogs - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Metastatic Pancreatic Cancer - Recent Pipeline Updates 137
Metastatic Pancreatic Cancer - Dormant Projects 186
Metastatic Pancreatic Cancer - Discontinued Products 187
Metastatic Pancreatic Cancer - Product Development Milestones 188
Featured News & Press Releases 188
Jan 07, 2014: ABRAXANE Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 188
Dec 17, 2013: Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study 189
Nov 22, 2013: Celgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 190
Nov 12, 2013: Final Results of Phase 3 Mastocytosis Study Expected by End of 2014 191
Oct 31, 2013: Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer 192
Oct 16, 2013: ABRAXANE Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine 193
Sep 30, 2013: Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013 194
Sep 12, 2013: Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress 194
Sep 11, 2013: Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer 195
Aug 28, 2013: Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer 196
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 199
Disclaimer 199
List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2014 11
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 23
Metastatic Pancreatic Cancer - Pipeline by Adherex Technologies Inc., H1 2014 24
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H1 2014 25
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2014 26
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 27
Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2014 28
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2014 29
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2014 30
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2014 31
Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H1 2014 32
Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2014 33
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 34
Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2014 35
Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 36
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2014 37
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 38
Metastatic Pancreatic Cancer - Pipeline by Insys Therapeutics, Inc., H1 2014 39
Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 40
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 41
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2014 42
Metastatic Pancreatic Cancer - Pipeline by AB Science, H1 2014 43
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2014 44
Metastatic Pancreatic Cancer - Pipeline by ParinGenix, Inc., H1 2014 45
Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H1 2014 46
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2014 47
Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H1 2014 48
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2014 49
Assessment by Monotherapy Products, H1 2014 50
Assessment by Combination Products, H1 2014 51
Number of Products by Stage and Target, H1 2014 54
Number of Products by Stage and Mechanism of Action, H1 2014 58
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 63
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2014 137
Metastatic Pancreatic Cancer - Dormant Projects, H1 2014 186
Metastatic Pancreatic Cancer - Discontinued Products, H1 2014 187
List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2014 11
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Top 10 Target, H1 2014 52
Number of Products by Stage and Top 10 Target, H1 2014 53
Number of Products by Top 10 Mechanism of Action, H1 2014 56
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 57
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Pancreatic Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Metastatic Pancreatic Cancer - Overview 11
Pipeline Products for Metastatic Pancreatic Cancer - Comparative Analysis 12
Metastatic Pancreatic Cancer - Therapeutics under Development by Companies 13
Metastatic Pancreatic Cancer - Therapeutics under Investigation by Universities/Institutes 16
Metastatic Pancreatic Cancer - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Metastatic Pancreatic Cancer - Products under Development by Companies 20
Metastatic Pancreatic Cancer - Products under Investigation by Universities/Institutes 22
Metastatic Pancreatic Cancer - Companies Involved in Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Adherex Technologies Inc. 24
AstraZeneca PLC 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
FibroGen, Inc. 28
Novartis AG 29
Pfizer Inc. 30
Celgene Corporation 31
Bayer AG 32
Halozyme Therapeutics, Inc. 33
Momenta Pharmaceuticals, Inc. 34
Immunomedics, Inc. 35
Synta Pharmaceuticals Corp. 36
NanoCarrier Co., Ltd. 37
Rexahn Pharmaceuticals, Inc. 38
Insys Therapeutics, Inc. 39
OncoMed Pharmaceuticals, Inc. 40
Merrimack Pharmaceuticals, Inc. 41
Pharma Mar, S.A. 42
AB Science 43
Oncovir, Inc. 44
ParinGenix, Inc. 45
Regulon Inc. 46
Fountain Biopharma Inc. 47
Oncozyme Pharma Inc. 48
AbbVie Inc. 49
Metastatic Pancreatic Cancer - Therapeutics Assessment 50
Assessment by Monotherapy Products 50
Assessment by Combination Products 51
Assessment by Target 52
Assessment by Mechanism of Action 56
Assessment by Route of Administration 60
Assessment by Molecule Type 62
Drug Profiles 64
paclitaxel albumin-bound - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
irinotecan sucrosofate liposomal - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
masitinib - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
cisplatin liposomal - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
cisplatin - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
refametinib - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
selumetinib sulfate - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
trametinib dimethyl sulfoxide - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
docetaxel - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
paclitaxel albumin-bound - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
ganetespib - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
RX-0201 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
irinotecan sucrosofate liposomal - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
PGX-100 - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
lurbinectedin - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
yttrium Y 90 clivatuzumab tetraxetan - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Cancer Inhibitor Macrobeads - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
TL-118 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
LY-2090314 - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
hydroxychloroquine - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
LY-2495655 - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
PEGPH-20 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
M-402 - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
pentamidine isethionate - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
veliparib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
galunisertib - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
ADH-1 - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
FG-3019 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
demcizumab - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
LCL-161 - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
bevacizumab - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
PD-0325901 + PF-05212384 - Drug Profile 130
Product Description 130
Mechanism of Action 130
R&D Progress 130
Poly-ICLC - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
rottlerin - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
FB-704A - Drug Profile 134
Product Description 134
Mechanism of Action 134
R&D Progress 134
LY-2109761 - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Ceramide Analogs - Drug Profile 136
Product Description 136
Mechanism of Action 136
R&D Progress 136
Metastatic Pancreatic Cancer - Recent Pipeline Updates 137
Metastatic Pancreatic Cancer - Dormant Projects 186
Metastatic Pancreatic Cancer - Discontinued Products 187
Metastatic Pancreatic Cancer - Product Development Milestones 188
Featured News & Press Releases 188
Jan 07, 2014: ABRAXANE Plus gemcitabine Receives European Marketing Authorization for First-Line Treatment of Patients with Metastatic Pancreatic Cancer 188
Dec 17, 2013: Onconova Announces Results of Interim Analysis of Metastatic Pancreatic Cancer Study 189
Nov 22, 2013: Celgene Receives Positive CHMP Opinion for ABRAXANE in Combination with Gemcitabine as Treatment for Patients with Metastatic Pancreatic Cancer 190
Nov 12, 2013: Final Results of Phase 3 Mastocytosis Study Expected by End of 2014 191
Oct 31, 2013: Cornerstone Pharmaceuticals Announces Initiation of Phase II Clinical Trial of CPI-613 in Patients With Locally Advanced or Metastatic Pancreatic Cancer 192
Oct 16, 2013: ABRAXANE Phase III Study of Patients with Metastatic Pancreatic Cancer Published in New England Journal of Medicine 193
Sep 30, 2013: Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013 194
Sep 12, 2013: Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress 194
Sep 11, 2013: Nuvilex Eyes FDA Fast Track After ABRAXANE Approved for Pancreatic Cancer 195
Aug 28, 2013: Merrimack Reaches Patient Enrollment Goal in the Phase 3 NAPOLI-1 Study of MM-398 in Late Stage Pancreatic Cancer 196
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 199
Disclaimer 199
List of Tables
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2014 11
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 14
Number of Products under Development by Companies, H1 2014 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Late Stage Development, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Metastatic Pancreatic Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 23
Metastatic Pancreatic Cancer - Pipeline by Adherex Technologies Inc., H1 2014 24
Metastatic Pancreatic Cancer - Pipeline by AstraZeneca PLC, H1 2014 25
Metastatic Pancreatic Cancer - Pipeline by Eli Lilly and Company, H1 2014 26
Metastatic Pancreatic Cancer - Pipeline by GlaxoSmithKline plc, H1 2014 27
Metastatic Pancreatic Cancer - Pipeline by FibroGen, Inc., H1 2014 28
Metastatic Pancreatic Cancer - Pipeline by Novartis AG, H1 2014 29
Metastatic Pancreatic Cancer - Pipeline by Pfizer Inc., H1 2014 30
Metastatic Pancreatic Cancer - Pipeline by Celgene Corporation, H1 2014 31
Metastatic Pancreatic Cancer - Pipeline by Bayer AG, H1 2014 32
Metastatic Pancreatic Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2014 33
Metastatic Pancreatic Cancer - Pipeline by Momenta Pharmaceuticals, Inc., H1 2014 34
Metastatic Pancreatic Cancer - Pipeline by Immunomedics, Inc., H1 2014 35
Metastatic Pancreatic Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2014 36
Metastatic Pancreatic Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2014 37
Metastatic Pancreatic Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2014 38
Metastatic Pancreatic Cancer - Pipeline by Insys Therapeutics, Inc., H1 2014 39
Metastatic Pancreatic Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2014 40
Metastatic Pancreatic Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 41
Metastatic Pancreatic Cancer - Pipeline by Pharma Mar, S.A., H1 2014 42
Metastatic Pancreatic Cancer - Pipeline by AB Science, H1 2014 43
Metastatic Pancreatic Cancer - Pipeline by Oncovir, Inc., H1 2014 44
Metastatic Pancreatic Cancer - Pipeline by ParinGenix, Inc., H1 2014 45
Metastatic Pancreatic Cancer - Pipeline by Regulon Inc., H1 2014 46
Metastatic Pancreatic Cancer - Pipeline by Fountain Biopharma Inc., H1 2014 47
Metastatic Pancreatic Cancer - Pipeline by Oncozyme Pharma Inc., H1 2014 48
Metastatic Pancreatic Cancer - Pipeline by AbbVie Inc., H1 2014 49
Assessment by Monotherapy Products, H1 2014 50
Assessment by Combination Products, H1 2014 51
Number of Products by Stage and Target, H1 2014 54
Number of Products by Stage and Mechanism of Action, H1 2014 58
Number of Products by Stage and Route of Administration, H1 2014 61
Number of Products by Stage and Molecule Type, H1 2014 63
Metastatic Pancreatic Cancer Therapeutics - Recent Pipeline Updates, H1 2014 137
Metastatic Pancreatic Cancer - Dormant Projects, H1 2014 186
Metastatic Pancreatic Cancer - Discontinued Products, H1 2014 187
List of Figures
Number of Products under Development for Metastatic Pancreatic Cancer, H1 2014 11
Number of Products under Development for Metastatic Pancreatic Cancer - Comparative Analysis, H1 2014 12
Number of Products under Development by Companies, H1 2014 13
Number of Products under Investigation by Universities/Institutes, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 50
Number of Products by Top 10 Target, H1 2014 52
Number of Products by Stage and Top 10 Target, H1 2014 53
Number of Products by Top 10 Mechanism of Action, H1 2014 56
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 57
Number of Products by Top 10 Route of Administration, H1 2014 60
Number of Products by Stage and Top 10 Route of Administration, H1 2014 61
Number of Products by Top 10 Molecule Type, H1 2014 62
Number of Products by Stage and Top 10 Molecule Type, H1 2014 63
